未登录

G

Gretchen M. Unger

veterans health administration (vha)

H指数:18

被引数:1,963

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

3D cell-culture strategy for screening novel agents in Fanconi anemia chemoprevention

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Tenfibgen nanoencapsulated RNAi feCK2 inhibits protein kinase CK2 and induces apoptosis in feline oral squamous cell carcinomas in vivo

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-12-010

PRE

Precision medicine approaches to Fanconi anemia oral cancer personalized prevention and treatment

CANCER RESEARCH

IF16.6

2020-08-150

PRE

CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer

PHARMACEUTICALS

IF4.8

2017-02-2114

OAAI

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

BREAST CANCER RESEARCH

IF5.6

2015-02-1158

OAAI

Mechanism and Efficacy of Sub-50-nm Tenfibgen Nanocapsules for Cancer Cell-Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma

MOLECULAR CANCER THERAPEUTICS

IF5.5

2014-08-0526

OAAI

Malignant Cell Specific Nanotherapeutic Targeting of CK2

EUROPEAN JOURNAL OF CANCER

IF7.1

2012-11-010

PREAI

DEVELOPMENT OF A NOVEL NANOENCAPSULATED CONTRAST AGENT DELIVERED INTRACELLULARLY TO ENHANCE MR IMAGING OF PROSTATE CANCER

JOURNAL OF UROLOGY

IF6.8

2012-04-010

PREAI

Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells

IF10.1

2012-02-0129

OAAI

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice

MOLECULAR AND CELLULAR BIOCHEMISTRY

IF3.7

2011-07-1536

OA

Protein kinase CK2 modulates TAp73 phosphorylation and suppresses apoptosis in head and neck cancer

CANCER RESEARCH

IF16.6

2011-04-010

PRE

Emergence of protein kinase CK2 as a key target in cancer therapy

IF5

2010-04-28186

OAAI

CK2 Modulation of NF-κB, TP53, and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2 Oligonucleotides In vitro or In vivo via Sub-50-nm Nanocapsules

CLINICAL CANCER RESEARCH

IF10.2

2010-04-1482

OAAI

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice

JOURNAL OF CLINICAL INVESTIGATION

IF13.6

2009-06-0893

OA

CK2: A key player in cancer biology

CELLULAR AND MOLECULAR LIFE SCIENCES

IF6.2

2009-04-24325

OA

EARLY DEVELOPMENT OF A NOVEL NANOENCAPSULATED CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING OF PROSTATE CANCER

JOURNAL OF UROLOGY

IF6.8

2009-04-011

PREAI

Systemic therapy with an antisense CK2 oligonucleotide induces tumor regression in orthotopic prostate cancer xenografts

JOURNAL OF UROLOGY

IF6.8

2006-04-010

OA

Development of the nanocapsule, a novel non-viral technology for tumor-specific delivery of large molecule cargo to prostate cancer cells

JOURNAL OF UROLOGY

IF6.8

2006-04-010

PRE

Targeted Nanocapsules for Liver Cell-Type Delivery of Plasmids In Vivo

MOLECULAR THERAPY

IF12

2006-01-011

OAAI

CK2 signaling in androgen-dependent and -independent prostate cancer

JOURNAL OF CELLULAR BIOCHEMISTRY

IF2.8

2006-01-0137

PREAI